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ABSTRACT
In the United States in 1948, the newly formed National Heart Institute (NHI) 
responded to what its data showed as a rising tide of coronary heart disease (CHD) 
by underwriting new approaches to the elucidation of chronic disorders. In the 
process, it funded the application of epidemiology, previously almost exclusively 
concerned with communicable disease, to study CHD. With federal encouragement, 
CHD epidemiologists enriched research designs, helped develop the randomized 
controlled trial, and played a pioneering role in chronic disease prevention at the 
individual and population levels. While government funding was critical to the 
evolution of this rich scientific work, a vibrant epidemiological imagination was 
able to capitalize on decades of national political commitment to chronic disease 
research. Epidemiologists developed longitudinal studies meant to determine the 
relationship between well-measured clinical variables and subsequent CHD events. 
Here, consistent associations within and across populations, eventually reinforced 
by analyses of pooled data from multiple cohort investigations, demonstrated the 
existence  of  well-founded  risk  factors,  but  left  open  the  question  of  causal   
inference based on observed relationships. After substantial ambivalence, the U.S. 
government,  under  pressure  from  epidemiologists,  committed  to  an  agenda  of 
clinical trials to test that proposition. In addition, the results of the cohort studies 
elicited a demand by epidemiologists for a broader, population-wide approach, 
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testing whether community-level models of risk factor modification through broad 
cultural change would demonstrate a reduction in the probability of disability and 
premature death from heart attack. 
To tell the story of the community studies and to analyze outcomes, we focus on 
the  Minnesota  Heart  Health  Program  and  the  Finnish  North  Karelia  Project.   
From the North Karelia experience, we find that health promotion campaigns in 
communities at very high risk of disease, where the population lives in traditional 
patterns and considerable poverty and is also unsophisticated in health knowledge 
and behaviors, are more likely to achieve major and measurable population effects. 
We argue that as chronic disease rates rise globally, and CHD rates increase in 
lower- and middle-income nations, as they have over the past several decades, 
population-level prevention interventions have become particularly relevant. But it 
remains to be seen whether the international community, prodded by its member 
states, can successfully reproduce the urgency and agenda-setting that sparked the 
successful epidemiologic and public health interventions in the affluent countries in 
the decades after World War II.
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INTRODUCTION
Following World War II, the United States Public Health Service made 
chronic disease, including coronary heart disease (CHD), the central focus 
of its biomedical program. It subsequently established new institutes of 
health for heart disease, arthritis, and neurological disorders, among others. 
In 1948, the newly formed National Heart Institute (NHI) responded to 
what  its  data  showed  as  a  rising  tide  of  CHD  by  underwriting  new 
approaches to the elucidation of chronic disorders. In the process, it funded 
the application of epidemiology, previously almost exclusively concerned 
with communicable disease, to study CHD. With federal encouragement, 
CHD  epidemiologists  enriched  research  designs,  helped  develop  the 
randomized controlled trial, and played a pioneering role in chronic disease 
prevention at the individual and population levels. Government funding 
was  critical  to  the  evolution  of  this  rich  new  science. A  vibrant  epi-
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political commitment to the elucidation of chronic disease. Although no 
initial agenda were set, the development of CHD epidemiology developed, 
paradigm-like, as findings generated new resolvable problems.
Deeply influenced by its wartime experience of funding research, the 
U.S.  government  committed  itself  through  its  health  agencies  and  tax 
dollars to study CHD, its cause and prevention, both intra- and extramurally.1 
These included, as the initial sections of this article show, longitudinal 
studies meant to elucidate the relationship between well-measured clinical 
variables and subsequent CHD events. Consistent associations within and 
across populations, eventually reinforced by analyses of pooled data from 
multiple cohort investigations, demonstrated the existence of well-founded 
risk  factors.  But  were  these  relationships  causal?  After  substantial 
ambivalence,  the  federal  government  committed  itself  to  an  agenda  of 
clinical trials to test that proposition. In addition, the results of the cohort 
studies generated a strong demand for a broader, population-wide approach, 
testing  whether  community  models  of  risk  factor  modification  would 
demonstrate a reduction in CHD morbidity and mortality. 
Although historians have begun to examine the development of the 
cohort studies and subsequent clinical trials, the story of the community 
studies has received little attention. The latter will form the bulk of this 
article. Specifically, the principal investigators of two of these community 
projects, the Minnesota Heart Health Program (MHHP) and the Finnish 
North Karelia Project, will describe the conditions whereby an aggregate of 
local interests committed themselves to an agenda of broad cultural change 
to reduce the probability of disability and premature death from heart attack. 
In depicting his program, each of these investigators, Henry Blackburn and 
Pekka Puska, respectively, brings his unique voice and experience. 
THE FORMATION OF AGENDA: CORONARY HEART DISEASE 
COHORT STUDIES
By the early decades of the 20th century, mortality data revealed that chronic 
non-infectious disorders such as cardiovascular disease (CVD) and cancer 
had become the leading causes of death in affluent cultures like the U.S. 
Along  with  insurance  companies  and  private  foundations,  the  federal 
government,  through  the  U.S.  Public  Health  Service  (PHS),  pioneered 
morbidity surveys that demonstrated the rising burden of chronic illness 
and disability.2 These results were deepened by the National Health Survey, 
conducted  by  the  PHS  between  1937  and  1938,  which  found  that 
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disease or physical impairment; half of these individuals were under 45 
years of age, often workers in their most productive stages of life.3 
Although there was growing interest in understanding, treating and 
controlling such disorders during the interwar years, marked, for example 
by the creation of the National Cancer Institute (1937), national efforts to 
understand and control chronic disease, CHD included, accelerated after 
World War II. 
In the early postwar years, epidemiology’s aim remained primarily the 
study of infectious disorders. Within the PHS, Joseph Mountin, director of 
its  Bureau  of  State  Services,  had  recently  created  the  Communicable 
Disease Center (later the Centers for Disease Control and Prevention), 
which  would  foster  epidemiology’s  application  to  such  diseases.4  But 
Mountin, a public health statesman and master of policy also struck a new 
direction. Strongly favoring disease control programs, initially developed 
for  infectious  disorders,  he  now  advocated  applying  them  to  chronic 
diseases and insisted on an epidemiological component.5,6 In pressing for a 
heart disease control effort, Mountin initiated a process that evolved into 
the Framingham Heart Study.7 
At that time, 1947, knowledge of what caused CHD was speculative. 
Clinical studies had implicated the possible role of dietary fat and elevated 
serum  cholesterol  in  the  development  of  an  underlying  atherosclerotic 
process.8 There was also evidence that serum lipid levels might be altered 
through dietary modification, an argument that environmental factors both 
caused and could possibly modify the risk of CHD.9,10 Based on mortality 
experience, insurance actuaries and clinicians suggested other determinants 
such as race, family history, age, sex, stress, blood pressure, smoking and 
alcohol consumption.11,12 Finding the etiology of CHD was of increasing 
importance as the weight of heart disease on mortality became a matter of 
grave concern. Employing the most inclusive category of death certification, 
cardiovascular-renal diseases, federal statisticians showed the death rates 
rising since the early 1920s, almost exclusively in white males.10,13 By mid-
century, they estimated that arteriosclerotic heart disease accounted for 
more than 22 percent of mortality, making it the leading cause of death.14 
During 1947 and 1948, its first years, Mountin’s Framingham Study 
was subject to a number of internal disputes, both personal and scientific. 
The dual nature of the study created a tension as to its purpose, only 
resolved when the control program was split from the epidemiological 
study and relocated to Newton, Massachusetts.7 In addition, precisely how 
epidemiology could be applied to CHD was a source of debate among the 
Framingham leadership. Unfortunately, Gilcin Meadors, the Public Health 454 PublicHealthReviews,Vol.33,No2
Officer  selected  by  Dr.  Mountin  as  principal  investigator,  had  sparse 
experience in fielding an epidemiological study; he ended by creating a 
design that included variables difficult to measure with precision, a short 
longitudinal horizon of five to ten years, and little indication as to how the 
data collected would be analyzed.7,15
The eventual success of the Framingham Study was due, in part, to the 
agenda of another veteran of the PHS, Cassius Van Slyke, the first director 
of the NHI, established in 1948. At his insistence, Dr. Mountin reluctantly 
transferred his study to the NHI the next year. Like Mountin, Van Slyke was 
interested in applying epidemiology to chronic disease and argued that 
research like Framingham should be integral to the Institute he headed. In 
the decades that followed, the NHI funded a substantial number of other 
longitudinal investigations proposed by independent investigators in an 
effort to measure the incidence of and risk factors associated with CHD in 
various  places  and  across  classes  of  race,  ethnicity  and  gender. These 
included cohort studies in Minneapolis, Albany, Los Angeles, Honolulu, 
Puerto Rico, Evans County (Georgia), and, later, in the cross-cultural Seven 
Countries Study.
Van Slyke directed his newly hired chief of biometrics, Felix Moore, to 
redesign the Framingham Study. Moore, a quantitative sociologist, brought 
to  Framingham  a  talent  for  applied  statistics,  expertise  in  writing  and 
scaling questionnaires, and the rigor of years of research work within the 
federal government.16 During Framingham’s first year under the NHI, he 
was probably the principal architect of its scientific transformation.17 With 
Meadors’ assistance and under Van Slyke’s critical eye, Moore redesigned 
Framingham into a 20-year study of individuals, initially free of arterio-
sclerotic disease, selected randomly from the town’s residents, both male 
and female, 30 to 59 years of age. Because Moore underestimated the 
refusal  rate  among  those  randomly  selected,  he  and  Meadors  had  to 
supplement the study with volunteers; ultimately comprising 14 percent of 
the cohort study’s 5,127 participants, they were found to have identical 
characteristics to the randomly sampled. The baseline variables initially 
chosen  by  Meadors  were  also  reexamined.  After  some  debate,  serum 
cholesterol level was included, as were body weight and blood pressure and 
the consumption of alcohol and tobacco. From the study’s start, clinical 
variables predominated, with little focus on psychosomatic, constitutional, 
or sociological determinants of heart disease, areas Meadors had included 
in his previous designs.18 
Under Van Slyke and his successors, the NHI continued Framingham as 
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surprisingly quickly. By 1956, the study’s principals, Thomas Dawber and 
William Kannel, reported that atherosclerotic heart disease was significantly 
associated with age and male sex. In men 45 to 62 years of age, for whom 
sufficient data existed, heart disease incidence was correlated with hyper-
tension, hypercholesterolemia and obesity.19 Framingham’s findings were 
corroborated by heart studies in Albany and Los Angeles (also supported 
by the NHI). Over the next decade, these cohort studies, and another in 
Minneapolis headed by Ancel Keys and funded by the PHS, would extend 
their findings. In 1960, for example, Framingham and Albany, combining 
data  to  achieve  greater  statistical  power,  demonstrated  a  significant 
association and dose-response relationship between cigarette smoking and 
myocardial infarctions and heart disease–related deaths.20 
The  agenda  of  the  NHI,  like  that  of  the  National  Cancer  Institute, 
included the formation of a cadre of superb statisticians to support the 
epidemiological work. By 1968, the Framingham study had published its 
first 66 articles, the start of a cascade of over 2,000 peer-reviewed pieces. 
This rate of publication in a variety of journals, well beyond that of other 
contemporary cohort investigations, assured Framingham’s prominence. 
As an intramural study of the NHI, its principals had a close working 
relationship  with,  in  addition  to  Moore,  statisticians  Jerome  Cornfield, 
Harold  Kahn,  and Tavia  Gordon. They  in  turn,  responding  to  analytic 
issues, developed important new statistical techniques, for example, those 
required to control for and summarize the multiple intercorrelated variables 
(more than 80 per Framingham participant) collected by cohort studies.21 
EQUIVOCAL COMMITMENT: THE EARLY RANDOMIZED 
TRIALS OF HEART DISEASE RISK FACTORS
The early cohort studies continued to show a consistency of results across 
different populations. They also found that the presence of more than one 
“risk factor,” a term newly coined in 1961, appeared to significantly raise 
the probability of CHD.22,23 In addition, epidemiologists learned that blood 
pressure and serum cholesterol level did not appear to have a cutoff below 
which individuals were without risk of the disease. Consequently, according 
to contemporary epidemiologists, almost every (male) U.S. adult was a 
potential  heart  patient.  With  no  effective  CHD  treatment  available, 
researchers argued that physicians, harnessing the new epidemiological 
evidence, should act to lower their patients’ risk of CHD morbidity and 
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Despite the growing evidence and the advocacy of epidemiological 
researchers,  many  physicians  remained  skeptics.  They  differed  among 
themselves over the importance of treating essential hypertension, usually 
acting when it was very high or underlying organic damage was evident. 
They remained uncertain as well whether blood cholesterol level affected 
CHD, a question linked to the debate over the pathogenesis of athero-
sclerosis.24
Did  any  of  the  designated  risk  factors  have  a  causative  role  in 
development of CHD? There was no direct evidence that reducing levels in 
those with high blood pressure, serum cholesterol or weight would lower 
CHD rates, producing outcomes similar to individuals with life-long lower 
numbers.  To  go  beyond  these  natural  limits  of  observational  studies, 
epidemiologists,  particularly  those  with  experimental  backgrounds  like 
Ancel Keys and Jeremiah Stamler, and clinical researchers like Irvine Page, 
looked to controlled clinical trials for an answer. In doing so, they turned to 
the NHI for support. 
The initial response of the National Institutes of Health (NIH), at least 
through the 1960s, was equivocal. In the late 1950s and early 1960s, it was 
unclear  to  scientific  researchers  and  federal  bureaucrats  whether  such 
experiments, using human populations, could be successfully engineered 
and completed. No one knew how well the quotidian consumption of food, 
medication or exercise could be accurately measured through long trials 
lasting five or more years. It was also unclear whether cadres of clinical 
professionals across multiple study sites could be socialized into researchers 
willing  to  follow  the  discipline  of  a  common  protocol.  The  question 
remained whether the results of such studies would be accepted by doctors 
and  patients,  ostensibly  their  ultimate  consumers.  Finally,  politically 
powerful scientists involved in laboratory and traditional clinical research, 
already suspicious of it, feared the investment of NHI dollars in clinical 
trials might put their own funding, status and scientific goals at risk.8
In the early 1960s, the NHI itself had little experience with randomized 
controlled trials (RCTs), particularly cooperative trials at multiple centers. 
The Institute had previously given statistical assistance to an international 
trial of cortisone, aspirin and ACTH in the treatment of rheumatic fever and 
its  consequences.25  Had  it  been  inclined,  it  could  have  looked  to  two 
controlled  trials  in  progress,  both  initiated  in  1959,  of  dietary  change 
(reduced saturated and increased polyunsaturated fats), subsequent serum 
cholesterol levels, and heart disease events, namely the Finnish Mental 
Hospital  Study  and  the Veterans Administration  Domiciliary  Study.26,27 
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Over the course of the decade, despite its inexperience, the NHI produced 
two significant trials. The first, the Diet-Heart Study, initially undertook the 
seemingly impossible task of testing the “coronary-genic” effects of the 
contemporary American  diet.  Prior  to  fielding  a  full  trial,  the  principal 
investigators proposed, and the NHI approved, a two-year feasibility study 
across six research centers, commencing in 1962. Its primary study design 
was a randomized, double blind, controlled trial using special commissary-
supplied, industry-prepared foods packaged to be indistinguishable, despite 
different fatty-acid composition for each arm.8 Its goal was to test whether 
diets lower in saturated fats and cholesterol would reduce serum cholesterol 
in  the  experimental  arms,  compared  to  controls  consuming  the  typical 
American regimen. In addition, the feasibility study tested basic questions 
on which a full, more extended trial would hinge. Among them were: Would 
middle-aged  men  volunteer  for  a  long-term  study?  Would  they  accept 
random assignment to a control group? Would they adhere to the experimental 
and control diets and thus lower their serum lipid levels? Was a double blind 
design workable? Would a non-blinded comparison using foods bought on 
the open market be adhered to and as effective in lowering serum cholesterol? 
And at what rate would volunteers drop out of the study?28
Although the two-year trial answered those questions in the affirmative 
and reported that the average cholesterol level for those in the experimental 
groups decreased by more than 11 percent by the end of the first year (a 
decline appreciatively different from baseline than that of the controls), the 
NHI refused to field the full study.8 Reasons for rejection included the large 
number of participants (between 49,000 and 219,000 depending on the 
endpoints used) and the high cost of such an investigation. In addition there 
was  continued  skepticism  as  to  whether  participants  would  remain 
compliant with the protocol over the course of a five-year study. There is 
also evidence that members of the primary advisory group to the director, 
the National Heart Advisory Council, composed primarily of prominent 
clinical  and  laboratory  researchers  and  academic  physicians  with  little 
knowledge and appreciation of population-based research, believed that the 
solution to CHD lay in their more traditional approaches. The final quietus 
occurred in late 1967, when an NHI review panel, headed by Edward 
Ahrens,  a  metabolic  and  clinical  researcher  at  Rockefeller  University, 
cautioned against the full study.29 A conclusion recommending against a 
national diet heart trial was made by another review panel that Ahrens 
chaired in 1970.30 
The second significant trial fielded by the NHI was the Coronary Drug 
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This trial, assayed the effect of cholesterol-lowering agents on rates of 
CHD events in men with heart disease. As a more traditional study, it 
garnered more support within the National Heart Advisory Council than 
had the Diet-Heart Feasibility Study. Its clinical outcomes, however, were 
deeply disappointing. Early on, three of the regimens, two doses of estrogen 
and a thyroid extract (dextrothyroxine) had to be discontinued when they 
were associated, respectively, with a raised rate of nonfatal heart attacks 
and excessive mortality. Another drug, Clofibrate, achieved no significant 
effect on the rate of adverse coronary outcomes but was associated with 
higher risk of thromboembolism and angina pectoris. A fifth agent, niacin, 
appeared to have some advantages over the placebo; because it did produce 
sustained reductions in serum cholesterol and triglycerides without serious 
side effects, the study made cautiously limited recommendations for its 
long term therapeutic use. 
What was remarkable about the CDP was the trial’s magnitude—over 
8,000 men and 53 study sites. The most successful outcome of the CDP, 
one might argue, was to develop an organizational model for administering 
large-scale cooperative trials, a model that became standard for the NHI. In 
summing up the results of the trial in 1975, Robert Levy, an expert on lipid 
disorders and director of the Institute, made that point.32 The CDP had 
demonstrated, he argued, that a multi-center clinical trial of CVD inter-
vention  was  possible.  Specifically,  physicians,  researchers  and  patients 
could be motivated to cooperate and to accept the discipline and constraints 
of a large clinical trial. 
INTEGRATING RANDOMIZED TRIALS INTO THE RESEARCH 
PROGRAM
Levy’s response mirrored a change in the Institute’s agenda. The late 1960s 
had  marked  a  policy  period  that  epidemiologist  Henry  Blackburn  has 
characterized as “The Pause.” The rejection of both the Diet-Heart Study 
and  a  large  multi-risk  factor  trial  proposed  by  Jeremiah  Stamler,  the 
University of Minnesota’s Henry Taylor, Michigan’s Richard Remington, 
and a group of other experts, left the NHI at an institutional impasse after 
1968. However, by the mid 1970s, the Institute pushed to formulate a new 
agenda in which RCTs were integrated into the research program.
Early in that decade, it appeared that the research position of the NHI 
was  being  superseded  by  other  health  organizations.  Domestically,  the 
Veterans Administration had initiated decisive RCTs of drug treatment for 
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anti-hypertension agents could significantly lower blood pressure in men 
with diastolic levels of 90 through 129 mm Hg and reduce hypertension-
related morbidity.33 Overseas, the World Health Organization promulgated 
a European Collaborative Trial of Multifactorial Prevention of Coronary 
Heart  Disease  in  1970  and  physicians  in  Norway  were  planning  what 
became the Oslo Diet-Heart Study, inaugurated in 1970.34,35 
It was in this environment that Theodore Cooper, Levy’s predecessor as 
director, established a Task Force on Arteriosclerosis in 1970 to formulate 
a long-range plan “to remedy current inadequacies, and to establish new 
directions of inquiry” to prevent and control arteriosclerosis.30(p.1) Among 
the many recommendations in its final report was that the NHI commit 
itself to conducting clinical trials of the major CHD risk factors. It argued 
that “the likelihood is high that a causal relationship exists between risk 
factors and the development of arteriosclerosis, and that a reduction in risk 
factors  will  decrease  the  incidence  of  the  clinical  manifestations  of 
arterioscerosis.”30(p.20) Although the task force advised against a national 
diet-heart trial, it stressed the need for multifactor, primary prevention trials 
using individuals with multiple elevated risk factors as preliminary to any 
action plan. “These trials will have the merit of demonstrating,” the report 
read, “whether or not intervention can prevent the complications of human 
arteriosclerosis since this is the crucial question as yet unanswered by 
direct experiment.”30(p.22) 
In his George Lyman Duff Memorial Lecture the next year, Dr. Cooper 
spoke about the emerging arteriosclerosis policy at the NHI. In his far-
ranging talk, Theodore Cooper recognized that all facets of biomedicine—
laboratory, clinical and population based—produced vital concepts and 
important congruent data.36 As he made clear in his lecture, he endorsed the 
Task  Force’s  strong  recommendations  for  clinical  trials  “to  study 
mechanisms and…test the preventive potential of practical public health 
measures.”36 Cooper called for a trial to test the relationship between blood 
pressure control and a reduction in CVD in various populations. He asked 
for a trial to test the practicality of broad risk factor reduction through a 
multifactorial clinical trial that included programs for smoking cessation, 
blood pressure control and bringing down serum cholesterol. Finally, he 
recognized the need for a trial of the lipid hypothesis, using participants 
with elevated blood lipids. 
Over almost 15 years, the Institute fielded trials already outlined by the 
Task Force and Theodore Cooper. In 1971, the renamed National Heart and 
Lung Institute funded the Hypertension Detection and Follow-up Program 
(1971-1982), a large, multicenter trial providing anti-hypertensive drugs to 
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directly by the Multiple Risk Factor Intervention Trial (MRFIT, 1972-1998), 
a large study of healthy men with elevated risk factors for coronary heart 
disease, and the Coronary Primary Prevention Trial (1973-1984), a test of 
the lipid hypothesis using the cholesterol lowering drug cholestyramine. 
Participants in the latter were men with primary hypercholesterolemia.
The MRFIT found no significant difference in disease experience risk 
factor  reduction  between  those  in  the  intensive  special  intervention 
program, who received hypertension treatment, dietary advice and smoking 
cessation counseling and controls who continued to receive their usual 
medical care.37 Risk factor levels in the special intervention group did 
decline:  cholesterol  levels  somewhat  less  than  expected  but  smoking 
cessation  was  substantial  and  the  reduction  in  diastolic  blood  pressure 
exceeded the study’s goal. But those in the usual care group also experienced 
sizable,  albeit  smaller  changes  in  all  three  factors,  contrary  to  the 
researchers’ initial expectation of no significant decline. Why the controls 
registered these unanticipated results was speculated upon at the time. 
Among reasons given, none mutually exclusive, were that voluntary trial 
participants,  regardless  of  their  randomized  placement,  may  have  been 
more conscious of health and open to change; perhaps participating in a 
trial for those at high risk for heart attacks may have had the effect of 
precipitating  behavioral  modification;  also  possible  was  that  new  heart 
healthy popular education and the ministrations of their own physicians 
may have been determinant, so that the statistical power of the trial was 
weakened by cultural transformation. Each of these speculative suggestions 
raised questions about the limitations of RCTs of intervention on lifestyle. 
The first and third of these primary prevention trials, however, had 
important  implications  for  “the  preventive  potential  of  practical  public 
health  measures”.  The  Hypertension  Detection  Follow-up  Program 
demonstrated the efficacy of drug therapy in men with mild hypertension 
(90 to 104 mm Hg), enlarging the pool of those eligible for such treatment.38 
And the outcome of the Coronary Primary Prevention Trial was interpreted 
by the Institute to support a causal relationship (thereby relieving the now 
National Heart, Lung, and Blood Institute (NHLBI), of its dilemma) as 
well as a campaign to lower blood cholesterol in the American population.39 
Whereas the first wave of controlled trials, like the Diet-Heart, did not 
succeed in having any clinical impact, this second wave decidedly did. 
Conversely, that impact helped sustain the luster of that expensive piece of 
technology, the RCT.
In the decade of the 1970s, a number of epidemiologists began to argue 
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conceptualizing it as a population or public health problem. Clinical trials, 
as just described, were aimed at “high risk” individuals. So too was the 
clinical medicine of the period. Clinical trials required years to complete and 
analyze. But cohort studies like Framingham and the Seven Countries Study, 
headed by Ancel Keys and his colleagues abroad, had already demonstrated 
reliable associations between risk factors and CHD; so did the cumulative 
evidence of the American Heart Association Pooling Project.40 Why not 
initiate community demonstration programs that aimed at preventing CVD 
by lowering a population’s risk factors? Would not transforming the culture 
of  a  community  be  more  effective  than  looking  to  change  individual 
behaviors? Given evidence that risk factor modification was safe, why not 
begin sooner rather than later? Commitment to such community prevention 
trials began in a number of countries under varying circumstances, and, with 
the exception of the early Stanford Three Community Study, led by John 
Farquhar, somewhat later in the U.S. than in Europe.41 
In  the  U.S.,  community-based  trials,  with  the  exception  of  John 
Farquhar’s  study,  were  held  in  abeyance  until  the  NHLBI  had  fielded 
significant RCTs of CHD risk factors. The Institute only committed itself 
to community trials in the early 1980s, in part goaded by congressional 
pressure and by the example of apparently successful programs in Europe, 
the North Karelia Project in particular. 
Once such demonstration projects became part of NHLBI’s research 
agenda, it funded trials in California, Rhode Island and Minnesota. The 
next  section  of  this  article  belongs  to  the  voice  of  Henry  Blackburn, 
principal investigator of MHHP, the largest of the community prevention 
trials begun in the U.S. in the early 1980s. Already a veteran epidemiologist, 
long associated with the Seven Countries Study and RCTs like the CDP 
and MRFIT, and an early advisor to the North Karelia Project, he brought 
the thread of all these experiences to the initiation of the MHHP.
The North Karelia Project, one of the first community-based trials, 
followed upon consistent findings by a component of the Seven Countries 
Study, the Finnish East-West Project, that North Karelians had the highest 
heart attack rates in the world. Community apprehension at multiple levels 
about  such  devastation  precipitated  a  strong  political  response.  The 
measured  result  was  a  coordinated  province-wide  demonstration  and 
research  agendum  drawing  on  government,  scientific  and  voluntary 
organizations, the media, food producers, clinicians and citizens of the 
region. In the final section, Pekka Puska, the project’s principal investigator 
from  its  inception  in  1972  through  1997,  describes  the  North  Karelia 
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COMMUNITY PREVENTION TRIALS INTRODUCED: THE 
MINNESOTA HEART HEALTH PROGRAM 
The idea of community trials or demonstration programs of CVD prevention 
in whole populations was a major leap of logic. It arose in the late 1960s 
from  independent  thinking  among  people  who  were,  nevertheless, 
communicating. It was first implemented in the early 1970s in Finland and 
at Stanford University. The MHHP had the same intellectual origin as the 
North Karelia Project; that is, in the large population differences in coronary 
disease rates associated with culture and diet that were documented for the 
first time in 1970 by the Seven Countries Study of Ancel Keys and an 
international team.42 
As already indicated, the leap of logic to community programs was 
intended, by the several pioneer groups involved, to by-pass an academic 
requirement of that time for experimental “proof” of causation by controlled 
trials among randomized individuals. The originators of the population-
wide approach accepted as sufficient for action the sound observational 
evidence then accumulated about the association of risk factors and actual 
risk, plus the evidence from clinical and laboratory studies congruent with 
causality for those risk factors. The different population rates and risk 
distributions among populations, combined with the experimental evidence 
that it was feasible and safe to modify personal risk characteristics by 
hygienic and pharmacologic interventions provided the rationale for the 
population-wide strategy. The object then became to carry out interventions 
with adequate designs for their evaluation.*43
Those holding this population view also questioned whether “proof” of 
cause by clinical trials was as strong, binding, or essential to scientific 
inference as purported; whether trial results from select affluent groups 
were generalizable to the whole population, and whether trials were more 
relevant  to  public  health  decisions  than  consistent  associations  found 
among “natural experiments” among contrasting traditional cultures. For 
the investigators at origin, these challenges of “proof” arose explicitly in 
* The biologic concept behind these efforts came from evidence that mass adult diseases in 
affluent societies are the result of ubiquitous and powerful environmental factors acting on 
wide  population  susceptibility.  The  environmental  factors  are  predominantly  culturally 
determined, socially learned behaviors. The population susceptibility is thought to be a human 
evolutionary legacy. Then, if whole communities are at excess risk of CVD, focus solely on 
the portion of highest risk appears to be a useful medical part of a community-wide prevention 
approach but is insufficient to interrupt or prevent epidemics. The several education strategies 
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the Panel on Causation of the Makarska Conference on Mass Field Trials in 
the Prevention of Coronary Heart Disease held in Yugoslavia in 1968.44
In any case, the story of the North Karelia community project has been 
well told, both later in this article and elsewhere.45 Minnesota’s community-
wide research agendum came from personal experience in the early years 
of the Seven Countries Study and encounters with the local activism in East 
Finland precipitated by that study’s findings. In East Finland, following the 
first survey in 1959, a bewildered delegation from the friendly populace 
presented, immediately after it was announced that their region boasted the 
world’s  highest  heart  attack  rates  and  had  the  world’s  highest  blood 
cholesterol levels! Following the 1964 survey, the local queries were more 
pointed and agitated: “Why us?” they asked. Then in 1969, with the record 
findings again verified, the confrontation became distressed. The people’s 
representatives were demanding that we help “do something about this 
terrible rate of heart attacks among us!”
Pekka Puska has described in the following section how this unique 
regional  situation  was  channeled  into  community  action,  importantly 
through the guiding hand of Finnish physician, Martti Karvonen. Finally, in 
fall 1971, Karvonen convened a WHO expert review group on the North 
Karelia Project plan. It included Jeremy Morris, social epidemiologist of 
London, and me. There we witnessed the community organizing for the 
challenge of its shocking and exceptional medical status. 
I  came  away  from  that  Finnish  scene  motivated  to  implement  a 
community model of CVD prevention for Minnesota. There would be, 
however, a sizable delay in its implementation as clinical trials and the 
more academic pursuit of the touted experimental “proof” took precedence. 
A  generation  of  randomized  clinical  trials  of  CVD  prevention  was 
initiated in fall 1971 with a national research policy announced by the 
National  Heart  and  Lung  Institute’s  director,  Theodore  Cooper,  at  the 
American Heart Association Scientific Sessions. It was at the same moment 
that North Karelia and the pilot Stanford community programs got under 
way. The new U.S. policy sought to satisfy the pressure on NIH from the 
vocal preventionist community calling for some public policy on heart 
attack prevention. It was to replace the proposal that the NIH had rejected 
in 1969 of a single-factor National Diet-Heart Trial, a study greatly feared 
by some in academia and by NIH staff because of its huge cost. It was also 
to counter the threat to U.S. leadership in CVD prevention by trials just 
undertaken in the United Kingdom, continental Europe, and Scandinavia. 
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Those investigators who participated in the 1968 conference on Mass 
Field Trials in the Prevention of Coronary Heart Disease, held in Makarska, 
Yugoslavia, along with a larger informed scientific community, had insisted 
for  several  years  that  if  proposed  public  programs  in  prevention  were 
unacceptable to the academy and the bureaucracy then “definitive trials” 
were the only rational alternative.46 As it turned out, we were quickly forced 
to “put up or shut up” and to help plan and carry out those complex, tedious 
trials, which many of us thought unnecessary in the first place. In that 1970s 
atmosphere, there would be trials, or nothing at all, for preventing heart 
attacks. 
Starting in 1972, the NIH funded a series of prevention trials into which 
virtually the whole of the U.S. CVD research community was drafted: the 
Hypertension Detection and Follow-up Program and other clinical trials 
already described, as well as various pharmaceutical approaches to blood 
pressure and blood lipid level lowering in patients and high-risk recruits 
and in whole communities. It was a frantically busy period during which 
the CVD prevention community was vastly expanded, as were its experience 
and competence.
By 1978, when we in Minnesota were over the hump in these trials, we 
were finally able to submit to NHLBI the first version of the proposed 
MHHP. Meanwhile, much had transpired on the national scene. Stanford 
University had completed its pilot Three Community Study with promising 
results and proposed a sophisticated Five City Study. A Memorial Hospital 
group in Rhode Island proposed the Pawtucket Heart Health Program. In 
the same period, the dramatic decline in age-specific death rates from CHD 
was  recognized  and  then  detected  widely  among  Western  industrial 
countries.  On  the  international  research  scene,  Gothenburg  University 
investigators in Sweden were intervening on multiple risk factors and WHO 
was coordinating the European Multiple Risk Factor Trial in Industry and 
launching comprehensive community control programs in chronic diseases 
on the continent.
On the other hand, much had not changed in the status of “proof” among 
the scientific leadership or in its priorities for obtaining ever-more evidence 
before recommending wide CVD prevention efforts. And as was usual, an 
elite of clinical and laboratory science leaders largely set those priorities 
and felt that they had already moved quite far conceptually in accepting and 
advancing the science of preventive trials. 
Early results from those trials in CVD appeared in the late 1970s and 
were mixed. Much of the leadership, therefore, was still not ready to make 
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other  than  anti-hypertensive  drug  therapy  among  high-risk  men.  “We 
simply don’t know enough to make recommendations to the public,” was 
the usual iteration.
The idea of community demonstrations of health promotion remained 
foreign,  as  well,  to  those  who  controlled  national  research  policy. An 
extended running-in period would be needed for NIH to develop competent 
review  for  such  new-fangled  ideas  as  “quasi-experimental”  community 
trials of CVD prevention! 
COMMUNITY TRIALS: AN INSTITUTIONAL NICHE IS FINALLY 
CREATED
A  niche  for  community  trials,  along  the  NIH  spectrum  of  laboratory, 
clinical, and population research and their applications, was eventually 
established during the early 1980s leadership by Robert Levy at NHLBI, 
where forward policy and political will for prevention surpassed that of all 
the  other  institutes.  Levy  confided  to  some  of  us  that  his  courage  in 
maintaining this view, against a large scientific community opposed to such 
use of funds, came from the ardent appreciation expressed by the United 
States Congress during his regular testimony before its committees. Thus, 
NHLBI was early and unique in translation and application of scientific 
endeavor to the public domain. It was something the Congressmen could 
take home, something which “value-free” basic science was not.
Eventually, three major U.S. community programs in CVD prevention 
were funded, at Stanford, Minnesota, and Rhode Island. At the outset, each 
had similar theory-based approaches but different strategic emphases and 
collaborative structures.47-49 
* I surmised at the time that a quintet of mature investigators with a population view of the 
origins of mass diseases might accurately and efficiently assess the design and management 
potential among proposals for community demonstrations. Instead, NIH was obsessed with 
providing specialists for each component of such programs, thus requiring cardiologists, 
nutritionists, multiple risk factor experts, behavioral scientists, statisticians and data managers, 
professional education experts, community organizers, screeners, communications specialists, 
school and youth program experts, etc.). This policy to cover all bases resulted in project 
evaluations by as many as two dozen narrowly focused experts, each jealous of his field and 
highly suspicious of generalists and “docs” leading the community efforts! A distribution of 
their review scores inevitably yielded an equivocal priority ranking rather than a fundable 
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THE MINNESOTA HEART HEALTH PROGRAM IS REALIZED
Minnesota strengths were considerable in the late 1970s for such a major 
community undertaking. We had several decades of experience sampling 
the  community  and  recruiting  from  it  for  various  interventions:  the 
Minnesota  Business  and  Professional  Men  Study,  the  Coronary  Drug 
Project,  MRFIT,  the  Lipid  Research  Centers  Prevalence  Study,  the 
Hypertension  Detection  and  Follow-up  Program  (HDFP),  and  the 
1979-funded Minnesota Heart Survey (MHS) of hospital surveillance and 
population-based risk factor surveys. From the mid-1970s, for MRFIT and 
its offspring studies, we had recruited to our department virtually all the 
staff expertise required for community interventions, excepting community 
organizers and media experts. These we soon found on our campus, with 
enthusiastic involvement from the Schools of Social Work and Journalism. 
Passing  over  the  obvious  hurdles  and  complexities  of  the  MHHP 
proposal to NIH, we had but to put pen to paper with our design for 
intervention and evaluation. By 1980, NIH peer-review had sufficiently 
“matured” that our effort was approved on a second go-round of review, as 
were those of Stanford and Rhode Island. Minnesota’s long experience 
with the “community-as-laboratory” led to what we thought a strong and 
balanced design for intervention and evaluation; strong, in that it involved 
sequential  entry  into  three  progressively  complex  communities  and 
matched comparison towns (thus, internal and external “controls,”) and 
because  it  gave  the  community  major  authority  in  program  direction; 
balanced, in that we assumed each intervention component was equally 
important among screening and direct education, community organization, 
and mass communications.49,50
At the outset, all three programs borrowed from social learning, network 
diffusion, and social marketing theory to bring their messages to individuals 
and the entire population of the educated towns. Stanford’s emphasis was 
on mass media interventions; its direction was top-down. Pawtucket (Rhode 
Island)  utilized  almost  entirely  existing  community  structures  for  its 
intervention.  These  three  models,  as  independent,  investigator-initiated 
grants,  would  have  made  useful  comparisons  of  intervention  and 
management strategy, but they were not to survive as independent entities. 
Almost at once, NIH, based on its perceived fiscal responsibility, sought 
closer oversight over its huge investment in the three programs and imposed 
an NIH-led Community Coordinating Committee (CCC). With repetitive 
meetings, updates, and nudging by the Committee, the strengths and ideas 
of each were assimilated by the others. The three soon became more and 
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MHHP DESIGN AND OPERATION
Clearly, much legwork in the several communities was required to make 
our proposal feasible and convincing, and we underwent two rigorous NIH 
site  visits  from  the  earlier-  described,  over-manned  groups  of  narrow 
specialists. We considered that several of our concepts for the intervention 
cities of Mankato, Fargo, and Bloomington were unique, over and above 
the three, paired communities design. For example, each had programs in 
its own name rather than in the name of the University of Minnesota; each 
its own director and board, community organizers, and locally appointed 
task forces (e.g., school, anti-smoking, physical activity, restaurant and 
supermarket  programs).  They  relied  on  the  Central  Executive  at  the 
University for advice and funding and on the University Media Unit for 
preparation and provision of small and large media. 
Meanwhile, the University faculty and staff had its matrix organization 
with an executive committee and an oversight board of national experts in 
community organization, communications, sampling, design and analysis, 
behavioral theory, and social marketing. All systems functioned reasonably 
well throughout. 
A main problem in direction during MHHP intervention was the long 
lag time to receive results of evaluation (aside from the appropriateness at 
all of evaluation of physical end points), and the difficult decision-making 
to innovate and introduce timely new strategies, versus redoubling efforts 
for an extant strategy that seemed to be lagging! The five-year plan left 
little time for extemporaneous corrections.
MHHP RESULTS
Surveillance  for  evaluation  of  MHHP  involved  several  programs:  1. A 
recurring cross-sectional community risk factor survey in both educated 
and comparison towns as the more stringent method to explore community 
time trends in risk; 2. Successive measurements of the same CVD risk 
factors  in  cohorts  participating  in  intervention  programs,  such  as  the 
screening clinics in educated communities; 3. Surveillance of coronary 
heart disease events in hospitals of all six communities; and 4.Various 
measures  of  program  “penetration”  and  impact,  including  numbers  of 
special program participants. 
A number of MHHP cohorts showed significant measurable changes in 
risk factors or behavior during and after the formal intervention period. The 
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educated and comparison communities experienced favorable risk trends. 
We found little solid evidence that the intervention was more influential 
than on-going changes in society, represented by the comparison towns. 
Stanford and Pawtucket community studies found pretty much the same in 
their  designed  cross-sectional  comparisons.  Each  study  involved  many 
campaigns and programs touching many thousands of people and achieving 
favorable behavioral and risk factor changes measurable in the cohorts, but 
the net cross-sectional differences in the physical measures were small and 
statistically not significant. The small number of cities in each study, and in 
all of the studies together, was also a limiting factor for analysis.
Individual program components were documented to be more and less 
well embraced and more and less apparently effective; for example, in 
MHHP, both hypertension control and physical activity levels showed good 
trends and school programs had measurable effects on delaying the age of 
taking up smoking and on healthy eating patterns at the school. Much was 
learned about how to enter and involve communities in health promotion, 
about specific effects of risk screening and direct education, and of media, 
about food demonstrations and lotteries, about community organization, 
and about the relevance of the various theoretical models of behavioral 
change, medical and population strategies.
Long after the intervention period, analysts from each of the three NIH-
sponsored U.S. efforts pooled the risk factor results from six educated and 
six comparison communities and summarized the overall contributions, 
here paraphrased.52 
The  studies  clearly  documented  major  risk  and  behavioral  changes 
during the period of the 1980s when large health changes were underway 
nationally, and they identified subgroup disparities in which some benefitted 
and others were little touched.
They devised and tested in diverse communities (but did not formally 
compare), a variety of interventions that were rapidly and widely adopted 
by groups in other community programs and for other issues such as the 
prevention  of  cancer,  osteoporosis,  diabetes,  and  obesity.  (MHHP,  for 
example, demonstrated that in the last years of the study the control towns 
“caught up” with the effects of early screening and education for cholesterol 
lowering in the educated towns.)
They summarized: “Favorable secular trends in both health promotion 
and risk factors made it difficult to demonstrate a specific intervention effect 
in the three U.S. trials.” Finally, they concluded that the apriori hypotheses 
(20%  change  difference  in  risk)  of  the  U.S.  studies  were  optimistic, 
“especially for community-based interventions, where even small reductions 
at the community level can have a significant impact on the public’s health”.52ResearchAgendaforCoronaryHeartDisease 469
The American experience with CHD community-based interventions 
owed a great deal to the creative epidemiology of the post-war decades, 
including the cohort studies and controlled clinical trials. It was also in debt 
to the earliest major CHD community project and evaluation program, one 
that stemmed directly from cross-cultural cohort studies organized in the 
U.S. and abroad. In the next section, Pekka Puska describes that project as 
it unfolded in Finland.
INTRODUCTION: THE NORTH KARELIA PROJECT: FROM CHD 
EPIDEMIOLOGY TO PUBLIC HEALTH
Before World War II, Finland was a very poor country, depending primarily 
on forestry and agriculture (mainly small dairy farms). Public health was 
dominated by infectious diseases, like tuberculosis, and high child and 
maternal  mortality.  After  the  war,  as  the  standard  of  living  gradually 
increased, infectious diseases were brought under control and public health 
improved. But new, chronic disorders emerged. Rates of CVDs, especially 
CHD, and lung cancer rose. Deaths from these diseases became common, 
even among quite young men. The popular assumption was that these 
diseases were related to hard work and aging.
In the medical community, CHD as a diagnostic entity had already 
become firmly established before the war. In 1947 a young demographer, 
Väinö  Kannisto,  published  his  doctoral  thesis  on  mortality  in  Finland, 
pointing out that mortality in eastern regions of the country had been higher 
than in the West since the 19th century, and that heart disease deaths there 
were particularly common.53 In 1953, Helge Honkapohja, who subsequently 
became head of internal medicine at the North Karelia Central Hospital, 
published an article in which he observed that by 1951, CHD had passed 
tuberculosis in number of deaths. Somewhat later, statistics showed that 
heart disease rates for Eastern Finland were the highest reported in the 
international tables. 
Coincidentally,  in  the  spring  of  1954,  Finnish  Professor  Martti  J. 
Karvonen visited the Laboratory of Physiological Hygiene of the University 
of Minnesota in Minneapolis and met its director, Ancel Keys. Since 1948, 
Dr. Keys had propounded his hypothesis on the chain of causation: dietary 
fat—high  blood  plasma  cholesterol—atherosclerosis  and  its  clinical 
manifestations in the cardiovascular system.54 This encounter provided the 
stimulus for the two leaders to join forces in 1956 to launch the first East-
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That  cross-sectional  study  appeared  to  support  the  cholesterol 
hypothesis: dietary intakes of saturated fats, as well as serum cholesterol 
values, were high by international standards, and both were higher in the 
East  than  the  Southwest.55,56  This  led  to  a  longitudinal  study  of  two 
contrasting populations of men in Finland, aged 40-59 years at entry in 
1959. As a component of the Keys-initiated Seven Countries Study, these 
cohorts of men were examined at five-year intervals for ten years and then 
followed to the present time. 
START OF THE NORTH KARELIA PROJECT
The Finish East-West findings over the first decade of the Seven Countries 
Study,  demonstrating  higher  rates  of  CHD  in  the  East,  buttressed  by 
published health statistics and the personal observations of people in the 
affected population, increasingly heightened popular concern. In January 
1971, the representatives of the Province of North Karelia, the eastern site 
of  the  East-West  study,  signed  a  petition  to  the  Finnish  government 
requesting urgent assistance to reduce its high CHD burden. 
Subsequently, under the encouraging guidance of Professor Karvonen, 
the Finnish Heart Association set up a planning group, including several 
Finnish experts. This led to a planning seminar in September 1971 in North 
Karelia, with several international WHO experts in attendance, among them 
Henry Blackburn of Minnesota and Jerry Morris of London. The meeting 
outlined the main principles of the North Karelia Project and recommended 
further steps: setting up the project organization, appointing the project 
director/principal investigator and selecting the core project team.
The  project  team  consisted  of  young  Finnish  doctors  and  social 
scientists, several of whom were veterans of radical student movements. 
They devoted their energy to fundamental change in the public health of 
North Karelia, based on new epidemiological findings barely mentioned 
during their medical studies. So radical was their approach and so limited 
their  scientific  experience,  that  the  team  at  first  faced  opposition  and 
suspicion  from  many  sources:  scientific,  cardiological,  political, 
administrative and economic—and particularly from the dairy industry. But 
when in 1973, the Ministry of Health turned to Geoffrey Rose, professor of 
epidemiology at the London School of Hygiene and Tropical Medicine as 
an outside consultant, he was quite positive, finding that the Project was 
“well designed in order to give a good chance of success” in testing “whether 
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During the early years, the North Karelia project had several influential 
supporters within Finland who helped assure its continuation. In addition to 
Professor Karvonen himself—whose academic standing was matched by 
his influence as Surgeon General of the Army—they included Leo Kaprio 
(Regional Director of WHO/EURO), Leo Noro (Director General of the 
National Medical Board), and the powerful governor of North Karelia, Esa 
Timonen. And, of course, the population was very interested and participated 
as well, although making lifestyle changes was not easy. 
During the planning phase, the young leadership of the project was 
faced with the enormous challenge of lowering such high CHD mortality 
rates. The common belief in contemporary medical circles was that the 
success of primary prevention was uncertain. The North Karelia study team 
thought otherwise. For the team it was obvious that clinical treatment, often 
too late, dealt with consequences—not causes. The team realized that the 
big  potential  for  CVD  control  was  in  primary  prevention,  while  in 
contemporary medical circles, the possibility of prevention was generally 
considered uncertain. The results of Framingham and other studies were 
reviewed in light of the situation in North Karelia, where smoking among 
men was markedly common, median blood pressure levels were raised, and 
serum cholesterol levels were extremely high, reflecting a traditional diet 
very high in saturated, especially dairy, fat). The decision was made to 
target these risk factors in the provincial population to test whether their 
levels could be lowered, and with that, heart disease rates.
The next question for the Project was one of strategy, of how to influence 
health behaviors. It was also understood that to reduce disease rates in the 
population, working solely with individuals at “clinically high risk” was 
insufficient. A population-based approach was needed to reduce the overall 
high levels of risk factors in the population.
This then was the background to the “community-based approach” for 
prevention  of  CVDs  for  the  North  Karelia  Project.  So  novel  was  the 
community  approach  in  the  early  1970s  that  a  1973  editorial  in  the 
InternationalJournalofEpidemiology criticized it with the title “shotgun 
prevention.”57 
PRINCIPLES OF THE NORTH KARELIA PROJECT
Although the main concepts of the North Karelia Project—a community 
based, comprehensive intervention to reduce the population level of risk 
factors and an evaluation design—were clearly formulated at the outset, 
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The original aim was to carry out the comprehensive preventive intervention 
in North Karelia for a five-year period (1972-1977). From the outset, the 
Project was seen as a pilot study for an intervention that might be applied 
to all of Finland, as it was in 1977; at the same time, it continued in North 
Karelia as a national “demonstration” or “model.” Its highly visible example 
presumably helped the national program to work. 
SUMMARY RESULTS OF THE NORTH KARELIA PROJECT 
The evaluation design and results of the North Karelia Project have been 
described in two summary monographs.58,59 During the initial five-year 
period, major changes were seen in diet; in addition, hypertension control 
was improved and smoking reduction reported among men. These and the 
associated changes in serum cholesterol and blood pressure levels continued 
in  North  Karelia  on  termination  of  the  local  intervention  while  major 
changes also took place in the rest of the country. 
Table 1 shows the change in the targeted risk factors in North Karelia 
from  1972  to  2007,  based  on  standardized  surveys  of  representative 
populations.60
Table 1
MainriskfactorsinNorthKareliabetween1972and2007
amongmenandwomenaged30-59years
Men Women
Year
Smoking
(%)
Serum 
cholesterol
(mmol/l)
Blood 
pressure
(mmHg)
Smoking
(%)
Serum 
cholesterol
(mmol/l)
Blood 
pressure
(mmHg)
1972 52 6.9 149/92 10 6.8 153/92
1977 44 6.5 143/89 10 6.4 141/86
1982 36 6.3 145/87 15 6.1 141/85
1987 36 6.3 144/88 16 6.0 139/83
1992 32 5.9 142/85 17 5.6 135/80
1997 31 5.7 140/84 16 5.6 133/80
2002 33 5.7 137/83 22 5.5 132/78
2007 31 5.4 138/83 18 5.2 134/78
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Fig. 1. Age-adjusted mortality rates of CHD in North Karelia and the whole of 
Finland among males aged 35-64 years from 1969 to 2006. 
Source: Puska P, et al., 200959
Figure 1 shows the reduction in age-standardized rates of the region’s 
CHD mortality rates, the primary objective of the North Karelia Project. In 
35 years, the annual age-adjusted CHD mortality rate among the 35-64 
year-old male population in North Karelia declined by 85 percent. But 
there was also reduction in CVD rates as a whole, and in many cancers 
among men (especially tobacco-related), and in all causes of mortality for 
both sexes, (Figure 1, Table 2). 
Table 2
 MortalitychangesamongmeninNorthKareliafrom1969-1971to2006
(per100 000;age35-64years)
Change in Mortality Rate From 1969-1971 to 2006
Mortality category North Karelia All Finland
Cardiovascular 80% 75%
Ischaemic heart disease 85% 79%
Cerebrovascular stroke 69% 73%
Cancers 67% 53%
All causes 63% 56%
Source: Puska P, et al., 200959474 PublicHealthReviews,Vol.33,No2
The relative decline in CHD mortality rates in North Karelia was clearly 
greater in the younger age groups, especially in men aged 35-44 (96%), but 
it was also found in older men, 65-74 years of age (69%). Nationally, 
moreover, during the project period (1972-1997), those in the 35-74 years 
age group experienced approximately 243,000 fewer deaths than estimated 
if mortality rates had stayed at the pre-program level. As a result of the 
improved adult mortality rates, the estimated life expectancy at birth in 
Finland rose from 66.4/74.6 years (males/females) in 1971 to 75.8/82.8 
years in 2006, and in North Karelia from 64/72 to 75/81. 
Separate analyses have shown that the observed reductions in population 
risk factor levels can account for most of the decline in CHD mortality.61 Of 
the single risk factors, reduction in serum cholesterol level had the greatest 
apparent impact. It is thus likely that most of the extraordinary decline in 
CVD  death  rates  has  been  due  to  primary  prevention.  We  have  not 
documented, but presume that concurrent improvements in medical therapy 
have also contributed to the favorable developments. 
LESSONS FROM THE NORTH KARELIA PROJECT
What  factors  have  been  most  important  in  the  design,  operation,  and 
interpretation of the Project? The answer to that question takes on salience 
as the North Karelia Project may influence programs in other resource poor 
countries. The development and administration of the Project led its team 
to consider the following: 
Appropriatetheory-base: The North Karelia Project epidemiologically 
adopted a community-based approach—shifting the risk factor distribution 
of  the  whole  population—targeting  changes  in  lifestyle  and  culture, 
especially diet and smoking patterns. The behavioral and social science 
theories developed for the Project dealt with issues of behavior change, 
communication-behavior  change,  innovation  diffusion,  and  community 
organization.62 These strategies were transferred to the national program, 
including broad policy involvement.63
Flexibleintervention: Although the North Karelia Project had a strong 
theoretical orientation, the actual intervention was flexible. Representatives 
of  the  Project  were  very  visible  and  interacted  closely  with  different 
organizations,  responding  to  the  particular  social  situations  of  each 
community. 
Intensiveintervention: Results of the Project did not depend on correct 
theoretical frameworks alone, but on much practical work. It was not enough 
to “do the right thing;” one has also “to do enough of it.” A commonly used 
phrase within the Project was to work with “boots deep in the mud.” ResearchAgendaforCoronaryHeartDisease 475
Workingwiththepopulation: From the very beginning, it was important 
to work closely with the community. The community “ownership” of the 
Project  was  considered  crucial,  as  it  was  launched  after  petition  by 
representatives of the people.
Communityorganization: “Community-based prevention” was the new, 
innovative approach to CVD in the early 1970s when many questioned 
whether CVD prevention was possible. From the start, the idea was to change 
North  Karelia  as  a  social  and  physical  environment,  because  individual 
behaviors tend to follow the general lifestyle patterns in the community.
Two principles were important. First, much of the Project’s success was 
based on personal contacts. Second, the aim was to find win-win situations, 
benefitting both the Project and the community. 
Officialauthority: Much of the Project’s work was based on voluntary 
collaboration, persuasion, training, and communication. At the same time, 
the Project was linked with official administrative structures and health 
authorities and, as much as possible, with national official guidelines and 
programs. This  emphasized  the  point  that  the  Project’s  involvement  in 
health services was not just some voluntary work, but an important part of 
official duties. In this way, the Project used a tactic of wearing “two hats”: 
an official and unofficial one.
In addition, the coordination of the Project was from within the National 
Public Health Institute, directly under the Ministry of Health, important for 
the continuation of the Project and for the transfer of its activities to the 
national level.
Workwithhealthservices: The intervention in North Karelia was broad 
and all possible areas of life were considered. But it was clearly realized 
that health services must form the backbone of the intervention. Within 
local health centers, public health nurses and physicians were considered 
key. Thus the Project established special and close contacts with them 
through training seminars, written materials and personal contacts.
Limitedtargets–outcomeorientation: The careful analysis of critical 
targets was found to be important, as was limiting the number chosen. 
“Less is more” is a phrase, often referred to. Also in the practical intervention 
these limited set targets were defined in terms of very practical behaviors, 
like switching from butter to soft margarines, choosing non fat (or low fat) 
milk, preferring lean meat, and increasing the consumption of vegetables. 
In addition, reduction of salt intake (also with replacement by low sodium 
salts) was stressed, as was smoking cessation. 
Bottom-up and top-down:  Health  promotion  discussion  often  asks 
whether to use a bottom-up or a top-down approach. In the North Karelia 
Project clearly a blended model was used. The project started in a bottom-up 476 PublicHealthReviews,Vol.33,No2
way, with the petition from the people to do something. This was heavily 
used and it was continuously emphasized that “Only you can change North 
Karelia.” At the same time, international and national expertise identified 
from a “top-down” perspective the objectives and the many interventions of 
the Project.
Although the Project was locally popular, the practical messages were 
not tempting: to change from butter to margarine in a dairy farming culture, 
to stop smoking when it was seen as a pleasure and of little harm to hard 
working men. Thus, the Project clearly had to act as a vigorous “change 
agent” to persuade and gradually introduce its innovations.
Monitoringandfeedback: The evaluation system and principles were 
defined at the outset. It was very soon realized that monitoring should serve 
more than evaluation. Monitoring of trends with feedback to people through 
the media was discovered to be one of the strongest intervention modalities. 
Rapid health behavior monitoring was started with active feedback to the 
population about the practical changes. This was later transferred to the 
national level as the national health behavior monitoring system. 
FromNorthKareliatothenationallevel: The original aim of the North 
Karelia Project was to carry out a comprehensive preventive intervention in 
North Karelia for a five-year period (1972-1977). In this way North Karelia 
was seen as a pilot study for all of Finland. After this period, many positive 
changes were already observed. Thus, the decision was made, encouraged by 
national authorities, to start to apply the Project experiences nationally, but at 
the same time to continue carrying out the project in North Karelia as a 
national “demonstration” or “model”. Both North Karelia and all of Finland 
would benefit from this. National interest helped sustain the North Karelia 
Project and the visible example of North Karelia helped the national work. 
CONCLUSIONS, IMPACT, AND IMPLICATIONS:
The long march of CHD epidemiology, beginning with the earliest cohort 
studies in 1947, has provided one model for the successful elucidation and 
prevention of chronic disease. The agenda for scientific study and for changes 
in morbidity and mortality were set both by government scientists at the 
highest levels and by the initiative and determined involvement of CHD 
researchers.  The  agenda  were  problem  oriented:  what  determined  the 
growing  rates  of  CHD  morbidity  and  mortality,  how  could  one  build  a 
scientifically based consensus on the causes of both, and how could the 
evidence of epidemiology and of bench and clinical science be actualized as 
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population level, in order to prevent or postpone the consequences of CHD? 
The pace and order of each step was not preordained, but evolved as new 
issues emerged from work in progress. At times, there was impatience with 
the rate of that pace, not only from communities of scientists and scientific 
administrators, but from the populations at risk, expressed in the U.S. through 
congressional committees and most piquantly in Finland from the leaders of 
a province characterized as having the world’s highest rates of CHD.
Given the evidence that has accumulated internationally about CHD 
prevention by risk factor differences and their reduction, the main question, 
by the 1980s was no longer “what should be done?” but “how should it be 
done?” The traditional answer had been to mobilize physicians to profile 
their patients, and to provide clinical counsel to them, especially those 
found to be at highest risk. RCTs, which generally focused on higher risk 
individuals,  were  methods  to  test  primary  and  secondary  treatment 
strategies  for  that  segment  of  the  population.  But,  as  this  article  has 
described,  an  essential  alternative  avenue  emerged  in  the  form  of 
community-based primary prevention, a total population approach. 
A  central  aim  of  those  community  programs  was  to  translate  the 
congruent findings of basic medical research to large-scale public health 
programs. The programs were theory-based attempts in real-life situations 
to overcome the many obstacles to healthy changes. A carefully evaluated 
community  program  thereby  served  as  a  demonstration  project  with 
potential  application  to  wider  populations  or  other  communities.  They 
proved, however, difficult to implement and to evaluate, in part because, like 
contemporary RCTs, they were interventions that occurred during a period 
of dynamic cultural changes that modified the prevalence of CHD risk 
factors and the level of medical treatment in the populations under study. 
Remarkable changes in the public’s health knowledge and behaviors, in 
cardiac care, and in medical preventive care were documented in American 
society in the 1980s. These were associated with an accelerated decline in 
coronary death rates at the rate of three to five percent a year both nationally 
and  in  California,  Minnesota,  and  Rhode  Island,  the  sites  of  the  U.S. 
community-based prevention initiatives. Initial and subsequent coronary 
disease mortality rates in Minnesota and California were relatively low 
overall. One conclusion is that placing the studies there was an unfortunate 
choice of area, population and timing, as low attack rates and rapid social 
changes reduced the power of the projects to achieve and measure inter-
vention effects.
It seems likely, from the North Karelia experience, that health promotion 
campaigns in a community at much higher risk, where the population lives 
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knowledge and behaviors at the outset, are more likely to achieve a major 
and measurable population effect than were the 1980s programs among a 
lower risk, more “sophisticated” and rapidly changing U.S. culture. But 
what industrial country can now meet such innocent conditions? And what 
designs  have  effectively  discriminated  effects  of  “natural  experiments” 
from planned interventions? 
The 1980s generation of studies in the U.S. neither produced such a 
design nor an efficiently powerful intervention to meet the extant design 
conditions. Moreover, those studies were not designed, or permitted to be 
designed, to discriminate among intervention strategies. Subsequently, the 
lack of net effect of these three programs on the cross-sectional population 
trends, over and above the large societal changes of the times, plus the 
complexity and cost of their design for evaluation and their vast inter-
ventions,  had  a  chilling  effect  on  U.S.  national  policy  for  research  in 
community health promotion. This was augmented by the very modest 
effect on community smoking levels of the giant NIH Commit Study in the 
1990s, with its random treatment assignment of 11 town pairs and its 
perhaps unfortunate focus on heavy smokers.64 
Epidemiologists have since promoted as primary goals the comparison 
of more limited strategies to achieve individual and population behavioral 
change, with designs to test the links between the intervention, the exposure 
(“dose”), and the resulting behavior change. They have suggested that such 
focused  trials  be  short-term,  with  frequent  small  surveys  for  greater 
statistical power.50,52,65-67
Based  on  the  remarkably  positive  U.S.  experience  in  discouraging 
tobacco use over the last 30 years, the “old saw” is still valid: that population 
strategies  (including  regulatory  components)  win  out  over  personal  or 
mediated  interventions,  at  least  for  diseases  or  conditions  of  wide 
susceptibility and strongly social origins.
If, as indicated above, communities of higher risk, like North Karelia in 
the 1960s, are the best candidates for successful community-based CHD 
programs, then changes in global health prevalence mark new areas for 
such preventions. When community trials of CHD prevention were started, 
CVDs were seen as “diseases of affluence,” as they mainly concerned 
industrialized  countries.  However,  over  the  past  several  decades,  non-
communicable diseases (NCDs) have moved to poorer and poorer nations, 
and within populations these diseases and their risk factors are increasingly 
accumulating  in  lower  socioeconomic  segments.  Thus  CVD  and  other 
chronic NCDs now greatly contribute to health inequality. 
The WHO has realized this new global health challenge, and it adopted, 
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that NCD prevention and control is now a priority of the organization, and 
that integrated primary prevention, targeting at the population level the 
main lifestyle-related risk factors, has the greatest potential for success.
WHO in 2008 intensified its work in the form of a special implementation 
plan for its global strategy. This is supported by recent risk factor-specific 
global instruments, including the WHO Framework Convention on Tobacco 
Control (2003) and the WHO Global Strategy on Diet, Physical Activity 
and Health (2004). Beyond WHO, the social, economic and population 
health consequences of CVD and other NCDs led to a Head of State-level 
Special United Nations Summit on NCDs in New York in September 2011.
The WHO strategies are deeply influenced by those followed by the 
North Karelia Project and similar community-based primary prevention 
studies. As the international community draws on the lessons of the North 
Karelia Project and those of U.S. and international community trials, it is 
tugging on a thread that connects it to previous agenda, the international 
series of RCTs that were once the fresh policies of the NIH and its analogues 
in other countries, and the long train of cohort studies that began in 1947 
and produced the paradigm of classic risk factors focused on today. From 
Framingham to North Karelia, significant groups of epidemiologists and 
organizations, despite conflict, negotiated scientific agenda with profound 
influence on population behaviors and public health strategies. It remains 
to be seen if the international community, prodded by its member states, 
can successfully produce the agenda required as chronic diseases become 
the most important disorders in low and middle income countries.
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